are now a part of the new and improved


Dermwire News

News | April 3, 2019

PellePharm: Phase 3 Trials for Patidegib for Gorlin Syndrome Underway

PellePharm, Inc., has dosed the first patient in a pivotal Phase 3 clinical trial of Patidegib Topical Gel, 2%, vs. vehicle gel in patients with Gorlin Syndrome. The Phase 3 study is intended to assess the safety and efficacy of patidegib...

Read More

News | April 2, 2019

Encore Dermatology Acquires Marketing Rights to Promius Pharma Brands

Encore Dermatology is purchasing the US rights to market Sernivo® (betamethasone dipropionate) Spray, 0.05% and is being assigned the rights to market and distribute Promiseb® Topical Cream and Trianex® 0.05%...

Read More

News | March 28, 2019

PALLAS Ti: Sapphire Solid State Laser Shows Similar Efficacy and Safety to 308nm Excimer Laser for Localized Vitiligo

A novel 311nm Titanium:Sapphire UV laser demonstrates comparable efficacy and safety when compared to 308nm excimer laser in the treatment of localized vitiligo, according to a study recently published in Lasers in Surgery and...

Read More
Thumbnail for gvhiwine
Play Button

Updates from Principia, Sebacia, and Candela

Series: DermWire TV | March 21, 2019

Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranded to reflect the unification of the Syneron and Candela brands. Dupixent from Regeneron Pharmaceuticals and Sanofi is now approved to treat atopic dermatitis in patients ages 12 through 17.

Watch Video

News | April 8, 2019

AIM at Melanoma Opens Melanoma Tissue Bank in the US

AIM at Melanoma celebrated the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. The Pittsburgh site is one of six...

Read More


The Latest News


View more